Pharma growth: AstraZeneca profit surges 77% to $2.53 bn in Q3; US expansion and cancer drugs power strong results
AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and robust sales of its cancer drugs. The pharmaceutical giant’s revenue climbed 12% to $15.2 billion, with oncology treatments now comprising nearly 44% of its total income. This performance underscores the company’s strategic focus on expanding its US operations and manufacturing footprint.🕒 1 min read
AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and robust sales of its cancer drugs. The pharmaceutical giant’s revenue climbed 12% to $15.2 billion, with oncology treatments now comprising nearly 44% of its total income. This performance underscores the company’s strategic focus on expanding its US operations and manufacturing footprint.
Continue Reading
- 7 Powerful Health Benefits Of Peanuts You Must Know This Winter
-
‘Don’t want to fight but …’: China blasts US over additional 100% tariff; calls out ‘double standards’
- Government plans special vessels to West Asia to ensure lower cost for exporters
- Vance, Rubio To Attend Winter Olympics, Trump Missing In List Of Attendees
-
UK Couple, Who Lived In Tent In Extreme Cold, Jailed Over Daughter’s Death
-
Facebook Friend ‘Sells’ Meghalaya Girl In Rajasthan For Rs 3 Lakh
- Forced Conversion, Rape, Blackmail: What Probe Team Found In Bhopal Case
- Eurozone inflation: Prices edge up to 2.1% in August, ECB likely to hold rates
-
AI talent wars: OpenAI requests court to dismiss xAI’s allegations; calls them ‘false and unsubstantiated’
-
‘Even die-hard fans won’t know their names’: Ex-India star slams Pakistan’s team
